PMC:7274968 / 4080-4309 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"78","span":{"begin":119,"end":126},"obj":"Species"},{"id":"82","span":{"begin":4,"end":17},"obj":"Disease"},{"id":"83","span":{"begin":30,"end":38},"obj":"Disease"},{"id":"84","span":{"begin":201,"end":207},"obj":"Disease"}],"attributes":[{"id":"A78","pred":"tao:has_database_id","subj":"78","obj":"Tax:9606"},{"id":"A82","pred":"tao:has_database_id","subj":"82","obj":"MESH:D001943"},{"id":"A83","pred":"tao:has_database_id","subj":"83","obj":"MESH:C000657245"},{"id":"A84","pred":"tao:has_database_id","subj":"84","obj":"MESH:D009369"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"For breast cancer, during the COVID-19 pandemic half of the centers (11/22, 50%) omitted radiotherapy boost unless the patient presented with significant risk factors of relapse (≤60 years, high-grade tumors, inadequate margins)."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T7","span":{"begin":4,"end":10},"obj":"Body_part"}],"attributes":[{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma9601"}],"text":"For breast cancer, during the COVID-19 pandemic half of the centers (11/22, 50%) omitted radiotherapy boost unless the patient presented with significant risk factors of relapse (≤60 years, high-grade tumors, inadequate margins)."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T3","span":{"begin":4,"end":10},"obj":"Body_part"}],"attributes":[{"id":"A3","pred":"uberon_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/UBERON_0000310"}],"text":"For breast cancer, during the COVID-19 pandemic half of the centers (11/22, 50%) omitted radiotherapy boost unless the patient presented with significant risk factors of relapse (≤60 years, high-grade tumors, inadequate margins)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T20","span":{"begin":4,"end":17},"obj":"Disease"},{"id":"T21","span":{"begin":11,"end":17},"obj":"Disease"},{"id":"T22","span":{"begin":30,"end":38},"obj":"Disease"},{"id":"T23","span":{"begin":201,"end":207},"obj":"Disease"}],"attributes":[{"id":"A20","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0007254"},{"id":"A21","pred":"mondo_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A22","pred":"mondo_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A23","pred":"mondo_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/MONDO_0005070"}],"text":"For breast cancer, during the COVID-19 pandemic half of the centers (11/22, 50%) omitted radiotherapy boost unless the patient presented with significant risk factors of relapse (≤60 years, high-grade tumors, inadequate margins)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T52","span":{"begin":4,"end":10},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"T53","span":{"begin":69,"end":71},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T54","span":{"begin":72,"end":74},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"}],"text":"For breast cancer, during the COVID-19 pandemic half of the centers (11/22, 50%) omitted radiotherapy boost unless the patient presented with significant risk factors of relapse (≤60 years, high-grade tumors, inadequate margins)."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T12","span":{"begin":4,"end":17},"obj":"Phenotype"}],"attributes":[{"id":"A12","pred":"hp_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/HP_0003002"}],"text":"For breast cancer, during the COVID-19 pandemic half of the centers (11/22, 50%) omitted radiotherapy boost unless the patient presented with significant risk factors of relapse (≤60 years, high-grade tumors, inadequate margins)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T35","span":{"begin":0,"end":229},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"For breast cancer, during the COVID-19 pandemic half of the centers (11/22, 50%) omitted radiotherapy boost unless the patient presented with significant risk factors of relapse (≤60 years, high-grade tumors, inadequate margins)."}